SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based...
Hence then, the article about vivacta bio announces promising first in human results for gt801 an in vivo car t therapy in non hodgkin s lymphoma at the 2025 ash annual meeting was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting )
Also on site :
- Jordan Peele’s Monkeypaw Productions and Universal Film Team With American Cinematheque and Beyond Fest for ‘No Drama’ Initiative (EXCLUSIVE)
- VMAs Producer Van Toffler on Nirvana & George Michael Tributes at 2026 Awards and Why the VMAs Are Best at Their Most ‘Age, Genre & Color Blind’
- ‘America’s Got Talent’ 2026 Finale Moves to New Time Slot Tonight: Here’s How to Watch